GlassScriptPhysician profile
Jesse S Dominguez
NPI 1467534313
$4,393.63
in general payments reported to CMS, 2019-2025
30 companies · $922 in 2025
The $922 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $350 · 2020: $109 · 2021: $243 · 2022: $660 · 2023: $1,112 · 2024: $998 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,031.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $592.10 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $542.86 | 2019-2025 | |
| Lilly USA, LLC | $525.99 | 2021-2025 | Jardiance, Zepbound, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $404.96 | 2022-2025 | |
| Novo Nordisk INC | $337.89 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $213.32 | 2019-2023 | Steglatro, Belsomra, Vaxneuvance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.31 | 2019-2025 | |
| Glaxosmithkline, LLC. | $160.06 | 2020-2025 | Shingrix, Arexvy, Bexsero |
| Astrazeneca Pharmaceuticals LP | $148.81 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Exact Sciences Corporation | $142.16 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $122.98 | 2019-2025 | Xifaxan |
| Biohaven Pharmaceutical Holding Company LTD. | $119.60 | 2022 | |
| Boston Scientific Corporation | $115.27 | 2019-2023 | Wavewriter Alpha Prime 16 |
| Astellas Pharma US INC | $105.92 | 2019-2024 | Veozah |
| Xeris Pharmaceuticals, INC. | $92.27 | 2023-2025 | Gvoke Hypopen, Keveyis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $87.58 | 2024-2025 | Repatha, Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $86.15 | 2020-2025 | |
| Sumitomo Pharma America, INC. | $58.44 | 2023 | Gemtesa |
| Mannkind Corporation | $56.59 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $44.83 | 2021-2022 | |
| Sanofi Pasteur INC. | $44.44 | 2023 | |
| Biohaven Pharmaceuticals, INC. | $43.51 | 2021 | |
| Intuitive Surgical, INC. | $33.84 | 2025 | |
| Janssen Pharmaceuticals, INC | $33.15 | 2019-2020 | |
| Edwards Lifesciences Corporation | $25.67 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Abbvie INC. | $24.43 | 2021 | |
| Phadia US INC. | $17.04 | 2024 | Immunocap |
| Teva Pharmaceuticals USA, INC. | $15.87 | 2019 | |
| Qiagen, LLC | $15.27 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $14.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jesse Dominguez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.